EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Low-Dose Versus Standard-Dose Bevacizumab Plus Sintilimab for Unresectable Hepatocellular Carcinoma: A Real-World Comparative Study of Efficacy and Safety

Lin Xu, Xiao Wang, Xiaohuan Lai, An Li, Ye Mao, Xu Wang, Jianbing Wu

Journal of Hepatocellular Carcinoma · 2026-04 · Volume 13 · 1-18

DOI: 10.2147/jhc.s582999 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2026-04. Verfasst von Lin Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

bevacizumabbleedinghepatocellular carcinomalow-dosesintilimab

Autor:innen und Institutionen

  • Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.
  • Department of Interventional Hepatology, The Fifth People's Hospital of Ganzhou, Ganzhou, Jiangxi, People's Republic of China.
  • Department of Oncology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, People's Republic of China.
  • Department of Pathology, The Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, People's Republic of China.

Zitieren

APA

Xu, L., Wang, X., Lai, X., Li, A., Mao, Y., Wang, X., & Wu, J. (2026). Low-Dose Versus Standard-Dose Bevacizumab Plus Sintilimab for Unresectable Hepatocellular Carcinoma: A Real-World Comparative Study of Efficacy and Safety. Journal of Hepatocellular Carcinoma, Volume 13, 1-18. https://doi.org/10.2147/jhc.s582999

Vancouver

Xu L, Wang X, Lai X, Li A, Mao Y, Wang X, et al. Low-Dose Versus Standard-Dose Bevacizumab Plus Sintilimab for Unresectable Hepatocellular Carcinoma: A Real-World Comparative Study of Efficacy and Safety. Journal of Hepatocellular Carcinoma. 2026;Volume 13:1-18. doi:10.2147/jhc.s582999

BibTeX
@article{Xu2026,
  author = {Xu, Lin and Wang, Xiao and Lai, Xiaohuan and Li, An and Mao, Ye and Wang, Xu and Wu, Jianbing},
  title = {Low-Dose Versus Standard-Dose Bevacizumab Plus Sintilimab for Unresectable Hepatocellular Carcinoma: A Real-World Comparative Study of Efficacy and Safety},
  journal = {Journal of Hepatocellular Carcinoma},
  year = {2026},
  volume = {Volume 13},
  pages = {1--18},
  doi = {10.2147/jhc.s582999}
}
Kostenlos starten →